Cited 0 times in
Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상준 | - |
dc.date.accessioned | 2014-12-19T16:42:48Z | - |
dc.date.available | 2014-12-19T16:42:48Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90050 | - |
dc.description.abstract | BACKGROUND: Bevacizumab has been extensively investigated in combination with various standard chemotherapies in the treatment of metastatic colorectal cancer (mCRC). However, a comparison to irinotecan + infusional 5-fluorouracil/leucovorin (FOLFIRI) is lacking. OBJECTIVE: To explore clinical effectiveness and cost-effectiveness of adding bevacizumab to a regimen of FOLFIRI for the first-line treatment of mCRC in the Republic of Korea by conducting an indirect treatment comparison. METHODS: A health-economic model was developed to investigate the possible health outcomes (life-years gained [LYG]), direct costs, and incremental cost-effectiveness ratio (ICER) of adding bevacizumab to a FOLFIRI regimen. Data on progression-free and overall survival were derived from randomized clinical trials and were used in the indirect treatment comparison. The annual discount rate for costs and outcomes was 5%. A lifetime horizon of 8 years was used. Sensitivity analyses were carried out on all pivotal model assumptions. RESULTS: Incremental mean overall survival among patients treated with bevacizumab + FOLFIRI varied between 8.6 and 15.7 months compared with patients treated with FOLFIRI alone. The deterministic base-case result was 1.177 LYG. The discounted ICERs ranged from μ31.8 to μ39.5 million/LYG, with the base-case result being μ34.5 million/LYG. Treatment effect had the most impact on the outcomes in this model. CONCLUSIONS: Although there is no formal threshold for ICER per LYG in Korea, funding may be considered for bevacizumab + FOLFIRI, particularly if the severity and end-of-life nature of mCRC is taken into account. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/analogs & derivatives | - |
dc.subject.MESH | Colorectal Neoplasms/drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms/pathology | - |
dc.subject.MESH | Cost-Benefit Analysis* | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Neoplasm Metastasis/drug therapy* | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Eui-Kyung Lee | - |
dc.contributor.googleauthor | Cedric Revil | - |
dc.contributor.googleauthor | Charles A. Ngoh | - |
dc.contributor.googleauthor | Johanna Lister | - |
dc.contributor.googleauthor | Jeong-Mi Kwon | - |
dc.contributor.googleauthor | Mee-Hye Park | - |
dc.contributor.googleauthor | Seok-Jin Park | - |
dc.contributor.googleauthor | Young-Suk Park | - |
dc.contributor.googleauthor | Sang-Joon Shin | - |
dc.contributor.googleauthor | Myung-Ah Lee | - |
dc.contributor.googleauthor | Nam-Su Le | - |
dc.contributor.googleauthor | Dae Young Zang | - |
dc.contributor.googleauthor | Eun-Jin Bae | - |
dc.contributor.googleauthor | Mi-Jeong Kang | - |
dc.identifier.doi | 22657254 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02105 | - |
dc.relation.journalcode | J00614 | - |
dc.identifier.eissn | 1879-114X | - |
dc.identifier.pmid | 22657254 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0149291812003190 | - |
dc.subject.keyword | antineoplastic combined chemotherapy protocol | - |
dc.subject.keyword | bevacizumab | - |
dc.subject.keyword | colorectal neoplasms | - |
dc.subject.keyword | cost-effectiveness | - |
dc.subject.keyword | indirect comparison | - |
dc.subject.keyword | Republic of Korea | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.citation.volume | 34 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1408 | - |
dc.citation.endPage | 1419 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, Vol.34(6) : 1408-1419, 2012 | - |
dc.identifier.rimsid | 32628 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.